Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-071349
Filing Date
2025-05-14
Accepted
2025-05-14 16:02:14
Documents
65
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q vor-20250331.htm   iXBRL 10-Q 1447747
2 EX-31.1 vor-ex31_1.htm EX-31.1 17188
3 EX-31.2 vor-ex31_2.htm EX-31.2 17174
4 EX-32.1 vor-ex32_1.htm EX-32.1 16823
  Complete submission text file 0000950170-25-071349.txt   6511453

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT vor-20250331.xsd EX-101.SCH 906459
67 EXTRACTED XBRL INSTANCE DOCUMENT vor-20250331_htm.xml XML 1175528
Mailing Address 100 CAMBRIDGEPARK DRIVE SUITE 101 CAMBRIDGE MA 02140
Business Address 100 CAMBRIDGEPARK DRIVE SUITE 101 CAMBRIDGE MA 02140 617-655-6580
Vor Biopharma Inc. (Filer) CIK: 0001817229 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39979 | Film No.: 25945157
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)